In the univariate analyses, clinical stages III and IV (HR, 2.536; 95% Cl, 1.050–6.125; P<0.039) and positive lymph node status (HR, 3.301; 95% Cl, 1.102–9.893; P<0.033) were associated with an increased risk of breast cancer-specific mortality, however, BRCA-1 positive status (HR, 0.209; 95% Cl, 0.048–0.902; P<0.036) was associated with a decreased risk of breast cancer-specific mortality (Fig. 3). The gene discussed is BRCA1; the disease is breast carcinoma.